Company Description
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer.
In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer.
It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG.
The company was founded in 2013 and is based in New Haven, Connecticut.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 27, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 246 |
| CEO | Randy Teel |
Contact Details
Address: 5 Science Park, 395 Winchester Avenue New Haven, Connecticut 06511 United States | |
| Phone | 203 535 1456 |
| Website | arvinas.com |
Stock Details
| Ticker Symbol | ARVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655759 |
| CUSIP Number | 04335A105 |
| ISIN Number | US04335A1051 |
| Employer ID | 47-2566120 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Randy Teel Ph.D. | Chief Executive Officer, President and Director |
| Andrew R. Saik | Chief Financial Officer and Treasurer |
| Angela M. Cacace Ph.D. | Chief Scientific Officer |
| Dr. Noah Berkowitz M.D., Ph.D. | Chief Medical Officer |
| David K. Loomis M.B.A. | Vice President and Chief Accounting Officer |
| Jeff Boyle | Vice President of Investor Relations |
| Jared M. Freedberg J.D. | General Counsel and Corporate Secretary |
| Steve Weiss | Senior Vice President and Chief Human Resources Officer |
| Lisa Sinclair | Senior Vice President of Corporate Operations |
| Paul McInulty | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | 144 | Filing |
| Feb 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 23, 2026 | 144 | Filing |
| Feb 23, 2026 | 144 | Filing |
| Feb 13, 2026 | 144 | Filing |
| Feb 13, 2026 | 144 | Filing |
| Feb 13, 2026 | 144 | Filing |
| Feb 13, 2026 | 144 | Filing |